⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18240070 | 0.76 | FYN (0.58) | — | |
| SCHEMBL27994196 | 0.75 | — | — | |
| SCHEMBL6628787 | 0.75 | — | — | |
| SCHEMBL172774 | 0.75 | — | — | |
| SCHEMBL9198455 | 0.75 | — | — | |
| SCHEMBL31619921 | 0.75 | — | — | |
| SCHEMBL12420722 | 0.75 | — | — | |
| SCHEMBL91450 | 0.75 | — | — | |
| SCHEMBL31628187 | 0.74 | NOS1 (0.42) | — | |
| SCHEMBL18735816 | 0.74 | NOS1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3107920-B1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | Bayer Pharma AG (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9688699-B2 | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| US-9688699-B2 | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3004094-B1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-8404662-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-1603570-B1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-4022897-A | 4H-PYRIDO(1,2-A) PYRIMIDIN-4-ONE DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1977-05-10 | — | — | US | disclosed |